A community nickname, taken apart
Wolverine peptide is a nickname, and Peptara Labs is the vendor we link. People also type it as the wolverine peptide stack or the wolverine stack peptide, for the same two compounds: BPC-157 and TB-500. The word came from a community, not a lab. For years, the clearest line on the pairing was a seller admitting no study had tested it. In 2026 one study did, and found no added benefit from combining the two over either alone.
Checked .
Links to Peptara Labs are affiliate links, and we may earn a commission when you buy through them.
Peptara Labs calls itself a research-grade peptide supplier and education resource, and it's the one vendor we link. It publishes third-party certificates of analysis on its /coa page, each from a recent batch. A certificate shows what one lot tested as; it does not show a product is safe or approved for use in people. That's the company describing itself, not our verdict. Read the Peptara Labs trust page and judge for yourself.
Wolverine peptide is an informal community name for BPC-157 combined with TB-500.
The name is taken from a fictional character in the comics, and it points at that character, not at any result.
There is no standardised formula behind it, and some sources also fold in CJC-1295 or Ipamorelin.
The evidence base behind those two compounds is described as largely preclinical, and one exploratory rat study in 2026 tested the pair and found no additional benefit over either compound alone, with no human trial of the pair on record.
The rest of this page is the long version of those four lines.
Wolverine peptide has four things on record. Each card below says what it is, in plain words, and points to the page with the details.
Both live answers traced the word to a fictional character in the comics. A nickname is a naming act, and it carries no finding across with it. What the name proves about a compound is nothing.
Read where a comics reference got attached to two compounds.
Both engines, checked the same day, said there is no standardised formula. Both also said some sources add CJC-1295 or Ipamorelin. Two people using the word can be describing two different sets of compounds.
See why two sources using this name may mean different things.
For years the only useful line came from the seller, which said no study had tested the pairing. In 2026 an exploratory rat study tested the two together and found no added benefit over either compound alone. A study exists now, and it is a null result.
One of the two named compounds has a certificate the vendor names by number, and this site downloaded and confirmed it. The other's certificate is published too, but this site did not open its files. One name, two compounds, two different depths of checking.
Both AI answers we checked on 2026-09-01 agreed: it's informal, it came from a community, and it's taken from a fictional character whose healing, in the comics, is the whole reason for the word. That's all we can stand behind.
A nickname is a name, not a finding. It doesn't carry any of the character's powers to a compound. We don't know who first typed it, when, or where, so we don't say.
Naming reference read on: Healthline, "What's the Wolverine Peptide Stack and Is It Safe?"
Both AI tools named the same two core compounds, BPC-157 and TB-500, and both said there's no standard formula. Then the wrinkle: some sources also fold in CJC-1295 or Ipamorelin under the same word.
Here's why that matters. Two writers can use the same phrase and mean different compounds, and you'd never be told. That's a fact about the word, not any compound. The two core compounds are also listed in the vendor catalog we link, where CJC-1295 with Ipamorelin is one combined entry.
Three compounds, each beside what's published about it separately. It's one of two tables here: this one is about the name, the one further down is about studies. It shows a grouping coming apart, not holding together.
| Compound, as sources write it | In the definition both engines gave on 2026-09-01 | Listed in the vendor catalog checked 2026-09-01 | Certificate record | Second-laboratory endotoxin report | How far this site went |
|---|---|---|---|---|---|
| BPC-157 | Named by both | Listed | Published | Published, by Janoshik | Downloaded, file type confirmed |
| TB-500 | Named by both | Listed | Published | Not published for this batch | Listed on the vendor page, not opened here |
| CJC-1295, with Ipamorelin | Added by some sources, per both | Listed as one combined entry | Published | Not published for this batch | Listed on the vendor page, not opened here |
The certificate column says Published for all three because the certificates page has a certificate for each, each from a recent batch. The second-lab column is a Janoshik bacterial endotoxin report, which some key batches carry and others don't.
Each row is about one compound on its own. Putting them in one table doesn't mean they belong in one vial.
Peptara Labs publishes an article about BPC-157 with TB-500. Written before the 2026 study, it treats each compound as having its own mechanism literature while noting the pair itself had not yet been trialled, so we read it as dated rather than wrong.
Yes, once, in 2026. A single animal study tested the pair in tendon-injured rats. The pair beat neither compound alone, and the authors called it preliminary, with no human data. The only human record is one small self-reported chart review. A 2026-09-05 literature search found 71 entries across the two compounds, and only eight name both.
The Peptara Labs article came before the study, so the study comes first here. More on the one study that tested the pair.
Sources: the 2026 animal study, the 2021 chart review, and the vendor article on the pairing.
Both AI tools, on 2026-09-01, called the evidence for these compounds largely preclinical. That's a location, not a verdict. It marks work not yet carried into human study. It isn't a promise that something works, or proof that it doesn't.
Since 2026-09-05 we name our sources, in the evidence table below, each one opened and checked. Most of that work is still preclinical: animal and bench models, not human trials of the pair. More on what that word marks, and what it does not.
Here we stop talking about the word and name records. Each row is a published source on one or both compounds, opened and checked on 2026-09-05. The reviews describe mostly preclinical work. The registered trials are listed for completeness: a registration tells you a study was filed, not what it found.
| Source | Year or status | Type | Compound, as recorded | What it covers | What it reports |
|---|---|---|---|---|---|
| PubMed 40005999 | 2025 | Review | BPC-157 | Pharmaceuticals literature and patent review: BPC-157 in models of tissue injury, inflammatory bowel disease and central nervous system conditions | Not approved for medical use; a temporary WADA listing noted in 2022 |
| PubMed 30915550 | 2019 | Review | BPC-157 | Cell and Tissue Research review: BPC-157 in animal models of musculoskeletal soft tissue injury | Discusses the limits of growth factor therapies |
| PubMed 40756949 | 2025 | Review | BPC-157 | HSS Journal systematic review: BPC-157 in orthopaedic sports medicine, across fractures, tendon, ligament and muscle injuries | No FDA approval, banned in professional sport, and rising use despite that |
| PubMed 41490200 | 2026 | Review | BPC-157, TB-500, GHK-Cu | Journal of the AAOS review: therapeutic peptides in orthopaedics | Describes BPC-157, TB-500 and GHK-Cu through angiogenesis, extracellular matrix remodeling and fibroblast activation, with growth hormone secretagogues treated separately |
| PubMed 41966639 | 2026 | Review | Approved and unapproved peptides | Sports Medicine review: peptides for musculoskeletal injury and performance | Describes a gray market of unapproved compounds outside regulatory oversight |
| PubMed 42578445 | 2026 | Review | BPC-157, thymosin beta-4 | A 2026 summary of peer reviewed data on six emerging peptides, BPC-157 and thymosin beta-4 among them | States an absence of efficacy or safety data for many emerging peptides |
| PubMed 42635865 | 2026 | Review | BPC-157, thymosin beta-4, TB-500, GHK-Cu | Current Pain and Headache Reports narrative review: peptides in chronic pain | Proposed mechanisms, preclinical and clinical evidence, safety and regulatory status |
| PubMed 41476424 | 2026 | Review | Peptides in orthopaedics | American Journal of Sports Medicine primer: peptide therapy in orthopaedics and sports medicine, written for surgeons | Sets out the current evidence behind peptide therapy |
| PubMed 42021992 | 2026 | Review | Peptides in aging | Frontiers in Aging narrative review: peptides in aging | Searches of PubMed, Scopus, FDA and WADA databases to January 2026 |
| PubMed 17495252 | 2007 | Review | Thymosin beta-4, full peptide | Annals of the New York Academy of Sciences review: coronary vessel development and neovascularization in animal models | Covers the full peptide, not the TB-500 fragment |
| NCT07437547 | Recruiting, phase 2 | Registered trial | BPC-157 | Acute hamstring muscle strain | A registration, which reports no outcome |
| NCT07803250 | Not yet recruiting, phase 1 | Registered trial | BPC-157 | Following rotator cuff surgery | A registration, which reports no outcome |
| NCT02637284 | Unknown status, phase 1 | Registered trial | BPC-157 (PCO-02) | Safety and pharmacokinetics | A registration, which reports no outcome |
| NCT07487363 | Recruiting, phase 1 and 2 | Registered trial | TB-500, the 17 to 23 fragment of thymosin beta-4 | Cardiovascular biomarkers in stable ASCVD | A registration, which reports no outcome |
| NCT04555824 | Completed, phase 1a | Registered trial | Thymosin beta-4, full peptide | Safety in volunteers | A registration, which reports no outcome |
| NCT05984134 | Completed, phase 2 | Registered trial | Thymosin beta-4, full peptide | Acute myocardial infarction | A registration, which reports no outcome |
| NCT00311766 | Terminated, phase 2 | Registered trial | Thymosin beta-4, full peptide | Wound outcomes in epidermolysis bullosa | A registration, which reports no outcome |
| NCT02974907 | Completed, phase 3 | Registered trial | RGN-259, a thymosin beta-4 eye drop | Dry eye syndrome | A registration, which reports no outcome |
TB-500 is a fragment of thymosin beta-4. A trial of the full peptide isn't a trial of TB-500, and we label them separately.
Peptara Labs LLC is registered in Wyoming, United States, Filing ID 2026-002031026, with a business address in Sheridan, Wyoming. It publishes third-party certificates of analysis and a 60-day money back guarantee on verified purity and fulfillment. We give you the record, not a verdict. See the Peptara Labs trust page.
Here's everything on record: reviews of mostly preclinical work, one exploratory rat study of the pair, one small retrospective human chart review, and a few registered trials with no results yet. None of it is advice for a person.
The one study of the pair measured outcomes four weeks after surgery. No human study of the pair gives any timeline, since the only human record looked back at charts. We don't restate trial schedules, and for the pair there's none to restate.
No. No photos, no paired scans. The study measured narrower things: load to failure, histology scores, collagen organisation. Those are tissue readouts, not a picture of a person.
We don't print prices. The vendor page does, and we just point to it.
BPC-157 has a paper trail, and it's worth reading before the nickname borrows its credibility. Batch testing is credited to Titreon Analytical, which the live page calls a third-party laboratory whose quality system is aligned to ISO/IEC 17025:2017, not itself accredited.
A certificate there covers seven things:
Each has a limit. HPLC purity is a relative peak area for one lot, not the amount in a vial and not proof of identity. LC-MS checks identity by mass: it fits the named compound but can't rule out a same-mass molecule. The fentanyl line is an immunoassay screen, which flags its target rather than identifying a sample.
The vendor names one certificate: COA-2026-8642, a four-page Titreon Analytical panel for BPC-157 batch BPC-260408-A. A separate lab, Janoshik, adds a bacterial endotoxin report on key batches, including this BPC-157 batch. Those reports have their own numbers, and Peptara Labs publishes a lot-number check for any lot on its certificates or reports. We didn't run that check.
We opened less than what's published. We downloaded the BPC-157 certificate, a four-page PDF, and the BPC-157 second-laboratory report, a PNG. Everything else on the verification write-up and the certificates page we call published and linked, not opened. More under the certificate identifier and the panel behind it.
TB-500 has its own published record, though thinner. The vendor lists a Titreon certificate for batch TB5-260415-A at 98.86 percent HPLC purity, and no Janoshik endotoxin report for that batch. So BPC-157 has both a Titreon certificate and a Janoshik report, and TB-500 has the Titreon certificate alone.
There's a second difference, on our side: we opened the BPC-157 files and no TB-500 file at all. The catalog as a whole reports measured purity from 95.48 to 99.62 percent. That range belongs to the catalog, so we don't pin it to TB-500 or BPC-157.
One nickname joins them, but each has its own certificate, and BPC-157's paperwork runs deeper. More under what this site opened for TB-500.
Because there's no shelf. By the vendor's own buying guide, these compounds aren't sold at any retail counter or pharmacy. They're sold as research-grade material, not as a drug cleared by any regulator.
So no product carries this name, and no ingredient panel anywhere can settle what belongs under it. The disagreement above isn't an oversight. It's what happens to a word that never had a label. More on why no ingredient panel settles this. We name one vendor, the one we link, and rank nobody.
The last column of the table above has four possible values. Each describes our effort, not quality. "Downloaded, file type confirmed" means we pulled the file on 2026-09-01 and checked its format, true only of two BPC-157 files. "Read on the live page" means we read it where the vendor published it. "Listed on the vendor page, not opened here" means we saw the link and didn't click. "Stated by the vendor, not tested here" means we're repeating a claim we couldn't check.
A ranked search on 2026-09-01 returned eleven domains. We opened and read exactly one, the Healthline page. The other ten we only recorded. Full method: what we opened and what we only recorded.
An informal community name, not a compound. On 2026-09-01 both AI answer tools defined it the same way: BPC-157 combined with TB-500, named after a fictional comics character. There's no standard formula. It's a label, not a product anyone publishes.
Source: Healthline.
It refers to a comic-book character whose healing, in fiction, is the point. A community applied it, not a lab or a regulator. It names an idea and transfers nothing to either compound.
Source: Healthline.
Both AI tools named BPC-157 and TB-500 as the core, and both said some sources add CJC-1295 or Ipamorelin. Both said there's no standard formula. So two sources using the name may not mean the same compounds. We give no amounts, ratios or order, because the name settles none of those.
Source: Healthline.
Partly, and it changed in 2026. The pair now has one exploratory rat study, which found no added benefit over either compound alone. A small 2021 retrospective chart review gave both to a few patients and logged self-reported results only. The wider literature is mostly reviews of preclinical work. Peptara Labs published its article before the rat study.
Source: the 2026 animal study.
We don't answer that for anyone, and we'll say so first. What's on record is narrow: one exploratory rat study found no added benefit from combining the two, one small retrospective chart review logged self-reported results, and reviews call the evidence largely preclinical. Material sold this way is research-grade, not a regulator-approved drug. No risk list and no reassurance here, because the record doesn't settle it.
Source: the 2026 animal study.
The one study of the pair couldn't show it beating either compound alone. In that exploratory 2026 rat study, BPC-157 and TB-500 on their own were each linked to better tendon histology than control, and TB-500 alone also showed a biomechanical advantage. The combined group added nothing over either. The authors called it exploratory and preliminary. In humans, there's one small retrospective chart review, self-reported and uncontrolled. That's a null result in animals and a thin human note, not a verdict for anyone.
Source: the 2026 animal study.
No study of the pair reports a time to any effect, and we won't invent one. The one study measured outcomes four weeks after surgery in rats. That's when the researchers looked, not when anything happens in a person. There's no human timeline and no schedule here.
Source: the 2026 animal study.
We don't print prices. No product carries this name, so there's no single price to quote, and the compounds are sold as research-grade material, not a retail product. The vendor we link lists its own prices.
Source: Peptara Labs, buying guide.
We won't state any effect in your body, because the record doesn't support it. Reviews describe proposed mechanisms, for the compounds, not the nickname. A 2026 Journal of the AAOS review discusses BPC-157 and TB-500 in terms of angiogenesis, extracellular matrix remodeling and fibroblast activation. A 2026 pain review lists proposed mechanisms with preclinical and clinical evidence. "Proposed" is the key word: these are ideas in the literature, not results in a person.
Source: PubMed 41490200.
No. BPC-157 is one compound with its own documents. The nickname points to a grouping with no standard formula. A certificate for one compound says nothing about any group it gets filed under.
Source: Peptara Labs, certificates page.
It says where the work sits: before human study. It's not a score, a promise or a refutation. Both AI tools used it for these compounds on 2026-09-01. Since 2026-09-05 we name individual records in the evidence table on this page, and most are reviews of preclinical work, not human trials of the pair.
Source: Peptara Labs, article on the pairing.
No. The vendor's own buying guide says no retail channel or pharmacy carries these compounds. They're sold as research-grade material, not a regulator-approved drug. Since no product carries the nickname, no ingredient panel fixes what it means. We rank nothing and compare nobody.
Source: Peptara Labs, buying guide.
There's no single product under this name, and we sell nothing. By the vendor's own buying guide, no retail counter or pharmacy carries these compounds; they're sold as research-grade material. The one vendor we link, Peptara Labs, lists BPC-157 and TB-500 in its research-grade catalog. We point to it and rank nobody.
Source: Peptara Labs, buying guide.
No. There's no standard formula and no product with the name, so there's no single wolverine stack item to add to a cart. BPC-157 and TB-500 are listed separately as research-grade material by the vendor we link. Two people buying "the wolverine stack" may end up with different compounds, because the name has no fixed contents.
Yes, two spellings of one nickname. People type wolverine peptide, wolverine stack and wolverine stack peptide for the same two compounds, BPC-157 and TB-500. On 2026-09-01 both AI answer tools defined it the same way. No spelling adds a compound or a finding.
Source: Healthline.
At the one vendor we link, batch testing is credited to Titreon Analytical, which the live page calls a third-party laboratory whose quality system is aligned to ISO/IEC 17025:2017, not itself accredited. One example is COA-2026-8642, a four-page panel for BPC-157 batch BPC-260408-A. A separate lab, Janoshik, supplies a bacterial endotoxin report on that same batch, one of the key batches that carries one. This covers one vendor only.
Source: Peptara Labs, certificates page.
On 2026-09-01 a ranked search for this phrase returned eleven domains: denverregenerativemedicine.com, musculoskeletalkey.com, youtube.com, orthopedicsri.com, facebook.com, healthline.com, ourfamilyhealthcenter.com, driphydration.com, womenshealthofmd.com, drsobo.com, agerejuvenation.com. We give no positions. We opened and read exactly one, the Healthline page, titled "What's the Wolverine Peptide Stack and Is It Safe?". We make no claim about the other ten, because we didn't open them.
Source: Healthline.
Peptara Labs is the vendor we link. It calls itself a research-grade peptide supplier and education resource, with a research-grade catalog, and it publishes third-party certificates of analysis where a batch has one. That's how the company describes itself. The judgement is yours.
Peptara Labs LLC is registered in Wyoming, United States, under Filing ID 2026-002031026, with a business address in Sheridan, Wyoming. It publishes third-party certificates of analysis and a 60-day money back guarantee on verified purity and fulfillment. Those are the facts. We draw no verdict.
Peptara Labs is registered in Wyoming, United States, as Peptara Labs LLC, with a business address of 30 N Gould St Ste 66115, Sheridan, WY 82801. That's a registration and mailing address, not a factory, lab or warehouse, and we add nothing. The filing ID is 2026-002031026.
Everything named here is research-grade material. This page is about a word a community attached to two compounds, and what is and isn't published behind it. The supplier we link isn't a medical provider. It doesn't diagnose, prescribe, supervise treatment or promise an outcome. Nothing it sells is an FDA-approved drug. Nothing here is medical advice or tells anyone what to take.
Yes, on its /coa page, each from a recent batch. Each certificate records identity, chromatographic purity against a not-less-than 95.0 percent release criterion, net peptide content, sterility, bacterial endotoxin, heavy metals and a fentanyl screen. We opened the BPC-157 certificate and record the rest as published and linked, not read. See the Peptara Labs certificates page.
